Table 1. Overview of recognized molecular targets, pharmacological agents, and clinical trials supporting their use in the treatment of MAFLD.

Molecular target	Therapeutic agent	Clinical trial
Nrf2 activation	Broccoli spout/sulforaphane	Randomized, placebo control, double-blind trial56
Neimann-Pick-C1 Like 1 inhibition	Ezetimibe	ESSENTIAL study57
IL1 antagonist	Canakinumab	CANTOS (cardiovascular trial)58
THRβ receptor agonist	Resmetirom	Phase 3 multinational trial59
PPAR agonist	Pioglitazone Lanibranor	TOSCA. IT55; PIVENS60; NATIVE (phase 2b)61